Showing posts with label Merck. Show all posts
Showing posts with label Merck. Show all posts

Thursday, October 14, 2010

Hawaii receives $82 million for pricing fraud

Pharmalot reports that the state of Hawaii will receive $82 million from large Pharma companies to settle the law suit that charged Pharma for overcharging the state in drug costs. In 1999, the cost of the program was $45 million, but had risen to $117 million in 2004. It was a Florida pharmacy that called out the overcharging. Merck will pay the largest sum of drug companies at $28 million, followed by Pfizer at $8 million.






Monday, July 12, 2010

Value Driven Pharma - 2010 Brochure Ready for Download

IIR’s 2nd Annual Value-Driven Pharma is not just another managed market event – it delves deeper than ever before to give you the tools to reconcile government, payer and patient perspectives on drug valuation to bring you closer to the patients you serve.
Explore risk-sharing contracts like CIGNA & Merck and Health Alliance & P&G, to evaluate the demand for more outcomes data from payers and the requirements around Comparative Effectiveness Research to pave the way for formulary placement from the earliest point possible in the development cycle.

Download the brochure to find out more about the speakers and presentations at this year's event:



Key Takeaways for 2010:
• Benefit from over 20 hours of face-to-face working groups, networking breaks, and roundtable luncheons.
• Tackle challenges that come with payers increased focus on innovation that supports better health and financial outcomes for patients
• Improve the relationship and communication between manufacturers and payers to align all the incentives behind improving patient value.
• Learn how to break free from organizational silos, to leverage CER data to craft a successful value proposition, and use risk-sharing contracting to ensure market access.






Monday, April 27, 2009

Drug Pricing Based on Patient Outcomes

According to this post in FierceHealthcare pharma companies have started adjusting pricing on their drugs to reflect its performance on improving patient outcomes. Merck has agreed to adjust pricing on Januvia and Janumet, which are diabetes drugs, based on how well they treat type 2 diabetes.

Performance-based pricing for meds is extremely rare, but with increased pressure coming from insurance companies it is only a matter of time before we will see more and more pharma companies following this pattern.

Read more about this piece on the NY Times